WEBULL
WebtradeDownload

Eli Lilly (LLY) Stock May Be 26% Below Fair Value On Richmond Plant Buildout

Simply Wall St · 1d ago

Eli Lilly has delivered a powerful run over the past few years, and with the stock recently closing at US$1,279.14, the key issue for investors is how well that price lines up with the cash the business is expected to generate.

  • Over 5 years, Eli Lilly has returned 436.9%, which puts a lot of weight on whether the current valuation still matches its underlying cash flows.
  • The company is pouring US$5b into a new Richmond manufacturing site for next generation cancer medicines, a move that can reshape future cash flow timing, margins, and capital needs as oncology programs scale.
  • If you'd rather focus on earnings, this one's for you. See what Eli Lilly's 42.7x P/E says about the price.

The stock's next move may depend on whether Eli Lilly's current share price is adequately supported by its projected cash flows under a Discounted Cash Flow (DCF) view.

If you want a wider starting point for research alongside Eli Lilly and its cash flows, a focused screen of 34 healthcare AI stocks can quickly surface other healthcare names linked to advanced therapies and AI.

Is Eli Lilly a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at what Eli Lilly could return to shareholders through future free cash generation. On this view, the latest twelve month free cash flow sits at about $13.6b, and the projection set has that figure growing rather than shrinking over time, which is a demanding setup for any pharmaceutical group.

What matters for you is that these cash flow assumptions still point to an estimated intrinsic value meaningfully above the current share price of US$1,279.14. Because Eli Lilly is committing around $5b to the new Richmond antibody drug conjugate facility, the model is effectively saying that even with heavy upfront investment, the expected cash returns justify a richer valuation than where the stock trades today. Find out what Eli Lilly could be worth using our Discounted Cash Flow (DCF) estimate.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the DCF leaves off by spelling out which paths for growth, margins, and earnings would need to play out for the stock to be worth materially more or less than today’s price. These narratives sit on the company’s Community page. Each narrative treats Eli Lilly's estimated worth as a thesis about the business that can be tracked over time rather than a one off snapshot.

Community views on Eli Lilly split between one camp that sees more upside tied to incretin drugs and another that worries the stock already prices in a lot of that story.

Bull case: roughly fairly valued

"Analysts expect Eli Lilly to keep building on its obesity and diabetes treatments and large-scale manufacturing build-out, with incretin medicines such as Mounjaro, Zepbound and Foundayo already supporting guidance for US$85b to US$87b of 2026 revenue and a 49% to 50.5% non-GAAP performance margin..."

Discover why this Narrative puts Eli Lilly at roughly fairly valued.

Bear case: 8% overvalued

"GLP-1 drugs are priced at $900-110 per month in the USA. This might be too much for most of the target market in the USA and overseas..."

Explore why this Narrative puts Eli Lilly at 8% overvalued.

Eli Lilly’s share price is only one piece of the decision

Before you treat Eli Lilly’s current valuation as the whole story, it is worth asking who is steering the business, how their pay packages are structured, and whether those incentives really align with your goals. See who runs Eli Lilly and how they are paid.